youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
A1ZN34:BVMF
Astrazeneca Plc Bdr
R$153.87
arrow_upward
+15.56%(+20.72) 1D
Oct 26, 3:47:02 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1ZN34...
Open
R$152.10
High
R$158.74
Low
R$152.10
Mkt. cap
265.72B
Avg. vol.
829.00
Volume
3.35K
52-wk high
R$190.40
52-wk low
R$129.06
Shares outstanding
1.55B
No. of employees
96K
Open
R$152.10
High
R$158.74
Low
R$152.10
Mkt. cap
265.72B
Avg. vol.
829.00
Volume
3.35K
52-wk high
R$190.40
52-wk low
R$129.06
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
TradingView
·
5 hours ago
REG - Niox Group PLC AstraZeneca PLC - Holding(s) in Company
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About Astrazeneca Plc Bdr
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com
Next call in 4 days
Fri, Oct 30, 10:30 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $2.58
Revenue / Est. (USD)
- / 16.00B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 15.19B | 15.50B | 15.29B | 15.38B |
Cost of goods sold | 2.79B | 3.17B | 2.67B | 2.53B |
Cost of revenue | 2.79B | 3.17B | 2.67B | 2.53B |
Research and development expenses | 3.63B | 3.62B | 3.47B | 3.67B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 5.20B | 5.32B | 5.03B | 5.72B |
Operating expense | 8.74B | 8.99B | 8.34B | 9.24B |
Total operating expenses | 11.53B | 12.16B | 11.02B | 11.78B |
Operating income | 3.66B | 3.35B | 4.27B | 3.61B |
Other non operating income | - | -247.00M | - | - |
EBT including unusual items | 3.24B | 2.63B | 3.91B | 2.80B |
EBT excluding unusual items | 3.32B | 3.05B | 3.94B | 3.24B |
Income tax expense | 709.00M | 300.00M | 833.00M | 291.00M |
Effective tax rate | 21.86% | 11.41% | 21.28% | 10.40% |
Other operating expenses | -89.00M | 53.00M | -155.00M | -152.00M |
Net income | 2.53B | 2.33B | 3.08B | 2.51B |
Net profit margin | 16.67% | 15.00% | 20.15% | 16.30% |
Earnings per share | 2.38 | 2.12 | 1.29 | 2.63 |
Interest and investment income | 85.00M | 135.00M | 73.00M | 80.00M |
Interest expense | -434.00M | -155.00M | -393.00M | -435.00M |
Net interest expenses | -349.00M | -20.00M | -320.00M | -355.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 5.21B | 4.11B | 5.64B | 5.19B |
Gain or loss from assets sale | -31.00M | -37.00M | -34.00M | -94.00M |